Procurement Checklist for FDA Compliant HCT/Ps

Procuring FDA-compliant human cellular and tissue-based products (HCT/Ps) requires verifying distributor and manufacturer registrations under 21 CFR Part 1271, auditing donor eligibility protocols, and maintaining strict cold-chain chain of custody. Practice managers and clinical administrators must establish a rigorous evaluation framework to ensure regulatory adherence, protect patient safety, and optimize procurement expenditure. Implementing a standardized checklist safeguards the clinic against regulatory compliance risks while ensuring high-quality biologics for clinical workflows.

The Regulatory Landscape for Human Cellular and Tissue Products

Human cellular and tissue-based products are regulated by the U.S. Food and Drug Administration (FDA) under 21 CFR Part 1271. These regulations mandate that tissue establishments meet current Good Tissue Practice (cGTP) requirements to prevent the introduction, transmission, or spread of communicable diseases.

When evaluating biologics for clinical integration, practice managers must differentiate between products regulated solely under Section 361 of the Public Health Service (PHS) Act and those regulated as biological drugs, devices, or biological products under Section 351.

Section 361 vs. Section 351 Criteria

To qualify as a Section 361 HCT/P, a tissue product must meet four distinct criteria:

1. Minimal Manipulation: The processing of the tissue does not alter the original relevant characteristics relating to the tissue's utility for reconstruction, repair, or healing.
2. Homologous Use: The tissue is intended to perform the same basic function or functions in the recipient as in the donor.
3. Non-Systemic / Non-Dependent: The product does not rely on the metabolic function of living cells for its primary function (or is for autologous use, allogeneic use in first- or second-degree blood relatives, or reproductive use).
4. No Combination: The product is not combined with another article, except for water, crystalloids, or sterilizing, preserving, or storage agents.

Products failing to meet any of these criteria are categorized as Section 351 biological drugs, requiring an approved Premarket Approval (PMA) or Biologics License Application (BLA) before distribution.

Procurement Checklist for FDA Compliant HCT/Ps

To standardize procurement and streamline compliance, practice leadership should execute the following checklist prior to onboarding any new tissue manufacturer or distributor.

1. Vendor & Manufacturer Regulatory Verification

• [ ] FDA Establishment Registration: Obtain copy of Form FDA 3356 showing active, annual registration with the FDA Center for Biologics Evaluation and Research (CBER).
• [ ] State Licensing: Verify the tissue bank and distributor hold appropriate state medical supply and tissue distribution licenses (e.g., Texas Department of State Health Services licensure where applicable).
• [ ] Accreditation: Check for voluntary accreditation by recognized bodies such as the American Association of Tissue Banks (AATB).

2. Donor Screening & Safety Controls

• [ ] Donor Testing Protocols: Confirm all donor tissue undergoes screening for communicable diseases (HIV-1/2, Hepatitis B, Hepatitis C, Syphilis, HTLV, West Nile Virus, and Chagas) at CLIA-certified laboratories.
• [ ] Summary of Records: Ensure every product shipment includes a Certificate of Analysis (CoA) and Summary of Records confirming donor eligibility prior to tissue release.
• [ ] Tissues Processing Environment: Verify processing occurs in ISO Class 5 cleanroom environments following strict cGTP standards.

3. Cold-Chain Logistics & Storage Integrity

• [ ] Temperature Monitoring: Confirm shipments include calibrated, continuous temperature data loggers or phase-change indicators.
• [ ] Validated Packaging: Ensure outer transport containers are validated for designated transit durations (e.g., 48 to 72 hours) under extreme ambient conditions.
• [ ] On-Site Storage Alignment: Audit clinical equipment to confirm capability for required storage temperatures (e.g., liquid nitrogen phase, -80°C ultra-low freezers, or ambient controlled storage).

4. Labeling & Practice Documentation

• [ ] Distinct Product Labeling: Confirm outer packaging clearly states donor identification, expiration dates, recommended storage conditions, and strict warnings regarding single-patient use.
• [ ] Tissue Tracking System: Confirm vendor provides standardized tissue tracking logs or barcoded labels to simplify tracking from receipt to patient administration as required by federal law.

Clinical Perspective: Tissue Integrity and Homologous Use

For attending physicians across specialties such as pain management and orthopedics, regulatory compliance translates directly to tissue viability and patient outcomes. Clinicians rely on distributors to provide allografts processed without chemicals or thermal steps that could alter the structural matrix or enzymatic components of the tissue.

Physicians must review product inserts to verify that the manufacturer's stated indications match homologous clinical applications. Integrating compliant allografts ensures that clinical decisions rest on predictable tissue performance while maintaining full compliance during external audits or hospital credentialing reviews.

Operational Perspective: Financial and Logistics Management

For practice managers and procurement administrators, handling tissue products requires strict financial control and supply chain efficiency. Key operational drivers include:

• Inventory Carrying Costs: Ultra-low temperature storage requires specialized equipment and continuous power redundancy. Practice administrators should align procurement volumes with expected clinical cadence to avoid holding excessive inventory.
• Waste Reduction & Expiration Tracking: Establishing a First-In, First-Out (FIFO) inventory control system minimizes product expiration risks. Sourcing from distributors offering flexible shipment schedules reduces stockouts while protecting practice cash flow.
• Consolidated Vendor Sourcing: Streamlining procurement by sourcing allogeneic tissue, autologous centrifuges, and clinical supplies through unified distribution channels reduces administrative overhead, simplifies invoice processing, and optimizes volume pricing discounts.

What This Means for Your Practice

Implementing a robust procurement protocol minimizes risk while building a reliable clinical foundation for advanced biologic procedures.

1. Conduct an Immediate Vendor Audit: Review all current tissue suppliers against FDA Form 3356 registration databases and request updated Summaries of Records for active stock.
2. Standardize Tissue Receipt SOPs: Train clinical staff to inspect physical temperature indicators upon package delivery and log lot numbers immediately into the patient record system.
3. Review Storage Capabilities: Ensure clinic freezers have calibrated continuous monitoring devices with automatic alert mechanisms for temperature excursions.
4. Align Clinical and Operational Goals: Hold quarterly procurement reviews between practice managers and treating physicians to evaluate product usage rates, inventory turns, and supplier reliability.

Practices seeking detailed guidance on compliant supply chain workflows can review our operational resources in our FAQ section.

Partnering with Compliant Biologics Distributors

Navigating tissue procurement requires a dedicated partner committed to compliance, chain-of-custody transparency, and clinical excellence. Dallas Regenerative Solutions works with licensed practices to deliver fully compliant biological products, surgical supplies, and procedural technologies tailored to practice workflows.

To evaluate your practice's procurement framework or request technical documentation for compliant allografts, contact our team today for a specialized practice consultation.